Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 FCF Margin % is -49.81% as of Mar. 2026. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Invicta Diagnostic ranks worse than 72.28% on this metric.
The historical rank and industry rank for Invicta Diagnostic's FCF Margin % or its related term are showing as below:
NSE:INVICTA'
s FCF Margin % Range Over the Past 10 Years
Min: -31 Med: -13.37 Max: 19.95
Current: -31
During the past 3 years, the highest FCF Margin % of Invicta Diagnostic was 19.95%. The lowest was -31.00%. And the median was -13.37%.
NSE:INVICTA's FCF Margin % is ranked worse than 72.28% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.41
vs NSE:INVICTA: -31.00
The historical data trend for Invicta Diagnostic's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic FCF Margin % Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
FCF Margin %
-13.37
19.95
-31.00
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
FCF Margin %
0.00
0.00
-13.90
-49.81
NSE:INVICTA vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic (NSE:INVICTA) has a FCF Margin % of -49.81% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Invicta Diagnostic and its competitors. According to the industry distribution chart, Invicta Diagnostic ranks #146 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 72.3%.
Is Invicta Diagnostic's FCF Margin % too high?
Invicta Diagnostic's current FCF Margin % is -49.81%. Based on the distribution chart, Invicta Diagnostic ranks #146 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #146 out of 202 companies for FCF Margin %. This places Invicta Diagnostic in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Invicta Diagnostic and its competitors. Invicta Diagnostic's current FCF Margin % is -49.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current FCF Margin % of -49.81%. The current FCF Margin % is -49.81%. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current FCF Margin % is -49.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
